Menu Search
Equities

Arch Biopartners Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ACHFF:QBB

Arch Biopartners Inc

Actions
  • Price (USD)0.6835
  • Today's Change-0.019 / -2.72%
  • Shares traded38.40k
  • 1 Year change-48.61%
  • Beta1.4396
Data delayed at least 15 minutes, as of Feb 13 2026 20:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.

  • Revenue in CAD (TTM)275.95k
  • Net income in CAD-1.55m
  • Incorporated2003
  • Employees--
  • Location
    Arch Biopartners Inc545 King St W.TORONTO M5X 1A1CanadaCAN
  • Phone+1 (647) 428-7031
  • Fax+1 (647) 351-3565
  • Websitehttps://archbiopartners.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.